Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
1001 results
D1.126 - Therapeutic Splenic Ultrasound Insonation as a Modulator of Pro-atherogenic and Pro-asthmatic Immune Inflammation: A Preclinical Study Design
D1.128 - Use of Tezepelumab in four Patients with Allergic Bronchopulmonary Aspergillosis and severe uncontrolled Asthma: A Case Series
D1.130 - Immune markers after one year treatment with benralizumab in severe eosinophilic asthma
D1.131 - Unconventional Group 2 Innate Lymphoid Cells Expressing C-Kit and IL-17A are Increased in Sputum from Severe Asthma with Mixed Granulocytic Airway Inflammation
D1.139 - Dupilumab was Effective in Black and Non-Black Patients with Asthma Completing 1 Year of the RAPID Registry
D1.14 - Biphasic, Refractory, and Persistent Anaphylaxis in Children
D1.140 - Beyond Severe Asthma: Eosinophilic Granulomatosis with Polyangiitis Unmasked by Acute Myopericarditis
D1.141 - Added value of impulse oscillometry in the early detection of small airway dysfunction in asthma
D1.142 - Clinical remission in long-term biological therapy of severe asthma
D1.143 - Clinical Efficacy of Biologics and ATAD in NSAID-Exacerbated Respiratory Disease: A Phenotype-Based Comparative Study
D1.145 - Clinical Impact of Type 2 Phenotype in Severe Asthma Patients with Exacerbations During Biologic Treatment
D1.146 - Improved nocturnal oxygenation in a severe allergic asthma patient with comorbid sleep apnea under anti-TSLP biologic therapy
D1.147 - Efficacy of benralizumab in Chinese patients with severe eosinophilic asthma: subgroup analysis of the 16-week results from STEP, a phase IIIb study of step-down maintenance therapy
D1.149 - Healthcare Professionals Typically Apply Higher Blood Eosinophil Count Thresholds for Biologic Selection Versus Clinical Guidelines in Severe Asthma
D1.150 - Patient characteristics and treatment patterns in adults with severe asthma in Poland (POLSAR): a retrospective, single-center real-world cohort from ISAR
D1.153 - Indirect Comparison of Biological Agents in Severe Asthma: Real-World Data
D1.154 - Mepolizumab treatment in a patient with severe eosinophilic granulomatosis with polyangiitis: a case report
D1.155 - Clinical, Functional and Inflammatory Characteristics of Young Adults with Bronchial Asthma Using Conventional Cigarettes, Electronic Nicotine Delivery Systems and Heated Tobacco Products
D1.156 - High relevance of upper airways comorbidities in T2 asthma inflammatory burden
D1.157 - Response to biologic therapy in severe asthma and chronic rhinosinusitis with nasal polyps according to nonsteroidal anti-inflammatory drug (NSAID) hypersensitivity
Pagination
First page
First
Previous page
Previous
…
Page
26
Page
27
Page
28
Page
29
Current page
30
Page
31
Page
32
Page
33
Page
34
…
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download